Sanofi has filed a patent for a method to express multiple target polypeptides in mammalian cells using unique cell surface markers. The method involves culturing cells, sorting based on marker expression, selecting high-expressing populations, and culturing for high target polypeptide expression. This innovation could advance protein expression technologies. GlobalData’s report on Sanofi gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sanofi, NSAID cancer drugs was a key innovation area identified from patents. Sanofi's grant share as of January 2024 was 60%. Grant share is based on the ratio of number of grants to total number of patents.
Method for high-level expression of multiple target polypeptides
See Also:
A recently filed patent (Publication Number: US20240035022A1) describes a method for expressing multiple target polypeptides at a high level. The method involves culturing mammalian host cells with recombinant polynucleotides containing unique cell surface marker and target polypeptide sequences. These cells are then exposed to detectable agents and subjected to fluorescence-activated cell sorting to select cells with high expression levels of the target polypeptides. Clonal populations with high expression levels of cell surface markers are further cultured to express the target polypeptides at a high level. The method allows for the selection and expression of multiple target polypeptides efficiently.
The patent also details the use of specific promoters, cell surface markers such as CD20, CD52, and CD59, and variants thereof. The engineered mammalian host cells, particularly CHO cells, contain multiple recombinant polynucleotides with bicistronic configurations for efficient expression of target polypeptides. The method can be applied to therapeutic proteins, antibodies, and other multi-chain proteins, offering a versatile approach for high-level expression of various target polypeptides. The patent highlights the importance of optimizing the expression levels of unique cell surface markers to achieve high expression levels of target polypeptides, showcasing a novel and efficient method for protein expression in mammalian cells.
To know more about GlobalData’s detailed insights on Sanofi, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
